Inhaled treprostinil improves walking distance in patients with pulmonary hypertension

Reuters Health - 13/01/2021 - Frequent daily inhalation treatment with the United Therapeutics drug treprostinil significantly increased the six-minute walking distance of people whose interstitial lung disease left them with pulmonary hypertension, doctors behind a new randomized clinical trial report. The 163 volunteers who got the drug four times per day via an ultrasonic pulsed-delivery nebulizer were covering 21 more meters after 16 weeks of therapy. But for the 163 patients who inhaled placebo, the distance covered by the end of the study had declined by 10 meters (P<0.001). The results of the company-funded study, known as INCREASE, were released in the New England Journal of Medicine. "When you add pulmonary hypertension onto interstitial lung disease, it makes the prognosis much worse and functional status declines rapidly," chief author Dr. Aaron Waxman of Brigham and Women's Hospital, in Boston, told Reuters Health by phone. "By treating ...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 13 January, 202126 January, 2021